Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030

Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight

The demand for organoids is being driven mainly by an increased preference for personalized medicine, a rising trend of using organoids as alternatives to animal testing, and their expanding application in cancer research, among other factors, throughout the forecast period from 2024 to 2030. The demand for organoids is being driven mainly by an increased preference for personalized medicine, a rising trend of using organoids as alternatives to animal testing, and their expanding application in cancer research, among other factors, throughout the forecast period from 2024 to 2030.

New York, USA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight The demand for organoids is being driven mainly by an increased preference for personalized medicine, a rising trend of using organoids as alternatives to animal testing, and their expanding application in cancer research, among other factors, throughout the forecast period from 2024 to 2030. DelveInsight’s Organoids Market Insights report provides the current and forecast market analysis, individual leading organoids companies’ market shares, challenges, organoids market drivers, barriers, trends, and key market organoids companies in the market.

Key Takeaways from the Organoids Market Report As per DelveInsight estimates, North America is anticipated to dominate the global organoids market during the forecast period. In the product type segment of the organoids market, the liver category had a significant revenue share in the organoids market in 2023. Notable organoids companies such as Thermofisher Scientific Inc.

, StemCell Technologies Inc., Qgel, DefiniGE, Cellesce Ltd, OcellO B.V.

, Hubrecht Organoid Technology (HUB), Organovo Holdings Inc., Takara Bio Inc., Corning Incorporated, and several others, are currently operating in the organoids market.

In February 2024, ATCC and Tissue Dynamics , a disruptive pharma-tech company integrating advanced artificial intelligence tools with bionic human organoids, announced a partnership to dev.